Short answer · Medically reviewed summary · Last updated: 2026-05-08
Miller Fisher Syndrome (MFS) is categorized under the ICD-10 code G61.0 for Guillain-Barré syndrome, as it is a rare variant of that condition, while the ICD-9 code is 357.0. Because Miller Fisher Syndrome is a specific clinical subtype, it does not have a unique, standalone ICD code, but is rather grouped within the broader inflammatory polyneuropathy classifications. What is the clinical classification of Miller Fisher Syndrome? Miller Fisher Syndrome is a rare, immune-mediated peripheral neuropathy characterized by the classic clinical triad of ophthalmoplegia (paralysis of eye muscles), ataxia (loss of muscle coordination), and areflexia (absence of deep tendon reflexes).
ICD10 code of Miller Fisher Syndrome and ICD9 code
ICD-10 and ICD-9 codes for Miller Fisher Syndrome, with classification details for clinicians, coders and patients.
Miller Fisher Syndrome (MFS) is categorized under the ICD-10 code G61.0 for Guillain-Barré syndrome, as it is a rare variant of that condition, while the ICD-9 code is 357.0. Because Miller Fisher Syndrome is a specific clinical subtype, it does not have a unique, standalone ICD code, but is rather grouped within the broader inflammatory polyneuropathy classifications.
What is the clinical classification of Miller Fisher Syndrome?
Miller Fisher Syndrome is a rare, immune-mediated peripheral neuropathy characterized by the classic clinical triad of ophthalmoplegia (paralysis of eye muscles), ataxia (loss of muscle coordination), and areflexia (absence of deep tendon reflexes). Because Miller Fisher Syndrome is a localized variant of Guillain-Barré syndrome, physicians use the overarching ICD-10 code G61.0, which encompasses various forms of acute inflammatory demyelinating polyradiculoneuropathy.
How is Miller Fisher Syndrome diagnosed?
Diagnosis of Miller Fisher Syndrome relies heavily on clinical presentation and the detection of anti-GQ1b ganglioside antibodies in the serum, which are present in approximately 85-90% of patients. Clinical testing often includes:
- Lumbar puncture to check for albuminocytologic dissociation in cerebrospinal fluid.
- Nerve conduction studies to assess peripheral nerve function.
- Neurological examination to confirm the hallmark triad of Miller Fisher Syndrome.
What is the prognosis for patients with Miller Fisher Syndrome?
The prognosis for Miller Fisher Syndrome is generally favorable, with most patients experiencing a self-limiting course of illness. Recovery typically begins within two to four weeks of onset. At DiseaseMaps.org, 36 people with Miller Fisher Syndrome have joined our community to share their experiences, noting that while the acute phase is distressing, the majority of patients achieve significant functional recovery with standard treatments like intravenous immunoglobulin (IVIG) or plasmapheresis.
Next steps
- Consult a neurologist immediately if you experience sudden double vision or loss of balance.
- Request a test for anti-GQ1b antibodies to confirm a Miller Fisher Syndrome diagnosis.
- Connect with the 36 members of the Miller Fisher Syndrome community on DiseaseMaps.org for peer support.
Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Miller Fisher Syndrome overview.
- Orphanet: Guillain-Barré syndrome (including Miller Fisher variant).
- National Institute of Neurological Disorders and Stroke (NINDS): Guillain-Barré Syndrome Fact Sheet.
- OMIM (Online Mendelian Inheritance in Man): Clinical entries on immune-mediated neuropathies.
